Valproic acid and epilepsy: From molecular mechanisms to clinical evidences

Michele Romoli, Petra Mazzocchetti, Renato D’alonzo, Sabrina Siliquini, Victoria Elisa Rinaldi, Alberto Verrotti, Paolo Calabresi, Cinzia Costa

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

After more than a century from its discovery, valproic acid (VPA) still represents one of the most efficient antiepileptic drugs (AEDs). Pre and post-synaptic effects of VPA depend on a very broad spectrum of actions, including the regulation of ionic currents and the facilitation of GABAergic over glutamatergic transmission. As a result, VPA indirectly modulates neurotransmitter release and strengthens the threshold for seizure activity. However, even though participating to the anticonvulsant action, such mechanisms seem to have minor impact on epileptogenesis. Nonetheless, VPA has been reported to exert anti-epileptogenic effects. Epigenetic mechanisms, including histone deacetylases (HDACs), BDNF and GDNF modulation are pivotal to orientate neurons toward a neuroprotective status and promote dendritic spines organization. From such broad spectrum of actions comes constantly enlarging indications for VPA. It represents a drug of choice in child and adult with epilepsy, with either general or focal seizures, and is a consistent and safe IV option in generalized convulsive status epilepticus. Moreover, since VPA modulates DNA transcription through HDACs, recent evidences point to its use as an anti-nociceptive in migraine prophylaxis, and, even more interestingly, as a positive modulator of chemotherapy in cancer treatment. Furthermore, VPA-induced neuroprotection is under investigation for benefit in stroke and traumatic brain injury. Hence, VPA has still got its place in epilepsy, and yet deserves attention for its use far beyond neurological diseases. In this review, we aim to highlight, with a translational intent, the molecular basis and the clinical indications of VPA.

Original languageEnglish
Pages (from-to)926-946
Number of pages21
JournalCurrent Neuropharmacology
Volume17
Issue number10
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Valproic Acid
Epilepsy
Histone Deacetylases
Anticonvulsants
Seizures
Glial Cell Line-Derived Neurotrophic Factor
Dendritic Spines
Status Epilepticus
Brain-Derived Neurotrophic Factor
Migraine Disorders
Epigenomics
Neurotransmitter Agents
Stroke
Neurons
Drug Therapy
DNA

Keywords

  • Epigenetics
  • Epilepsy
  • Epileptogenesis
  • Neuroprotection
  • Pharmacology
  • Valproic acid

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Romoli, M., Mazzocchetti, P., D’alonzo, R., Siliquini, S., Rinaldi, V. E., Verrotti, A., ... Costa, C. (2019). Valproic acid and epilepsy: From molecular mechanisms to clinical evidences. Current Neuropharmacology, 17(10), 926-946. https://doi.org/10.2174/1570159X17666181227165722

Valproic acid and epilepsy : From molecular mechanisms to clinical evidences. / Romoli, Michele; Mazzocchetti, Petra; D’alonzo, Renato; Siliquini, Sabrina; Rinaldi, Victoria Elisa; Verrotti, Alberto; Calabresi, Paolo; Costa, Cinzia.

In: Current Neuropharmacology, Vol. 17, No. 10, 01.01.2019, p. 926-946.

Research output: Contribution to journalReview article

Romoli, M, Mazzocchetti, P, D’alonzo, R, Siliquini, S, Rinaldi, VE, Verrotti, A, Calabresi, P & Costa, C 2019, 'Valproic acid and epilepsy: From molecular mechanisms to clinical evidences', Current Neuropharmacology, vol. 17, no. 10, pp. 926-946. https://doi.org/10.2174/1570159X17666181227165722
Romoli M, Mazzocchetti P, D’alonzo R, Siliquini S, Rinaldi VE, Verrotti A et al. Valproic acid and epilepsy: From molecular mechanisms to clinical evidences. Current Neuropharmacology. 2019 Jan 1;17(10):926-946. https://doi.org/10.2174/1570159X17666181227165722
Romoli, Michele ; Mazzocchetti, Petra ; D’alonzo, Renato ; Siliquini, Sabrina ; Rinaldi, Victoria Elisa ; Verrotti, Alberto ; Calabresi, Paolo ; Costa, Cinzia. / Valproic acid and epilepsy : From molecular mechanisms to clinical evidences. In: Current Neuropharmacology. 2019 ; Vol. 17, No. 10. pp. 926-946.
@article{c4890305752f48f19c74801697b7e7ed,
title = "Valproic acid and epilepsy: From molecular mechanisms to clinical evidences",
abstract = "After more than a century from its discovery, valproic acid (VPA) still represents one of the most efficient antiepileptic drugs (AEDs). Pre and post-synaptic effects of VPA depend on a very broad spectrum of actions, including the regulation of ionic currents and the facilitation of GABAergic over glutamatergic transmission. As a result, VPA indirectly modulates neurotransmitter release and strengthens the threshold for seizure activity. However, even though participating to the anticonvulsant action, such mechanisms seem to have minor impact on epileptogenesis. Nonetheless, VPA has been reported to exert anti-epileptogenic effects. Epigenetic mechanisms, including histone deacetylases (HDACs), BDNF and GDNF modulation are pivotal to orientate neurons toward a neuroprotective status and promote dendritic spines organization. From such broad spectrum of actions comes constantly enlarging indications for VPA. It represents a drug of choice in child and adult with epilepsy, with either general or focal seizures, and is a consistent and safe IV option in generalized convulsive status epilepticus. Moreover, since VPA modulates DNA transcription through HDACs, recent evidences point to its use as an anti-nociceptive in migraine prophylaxis, and, even more interestingly, as a positive modulator of chemotherapy in cancer treatment. Furthermore, VPA-induced neuroprotection is under investigation for benefit in stroke and traumatic brain injury. Hence, VPA has still got its place in epilepsy, and yet deserves attention for its use far beyond neurological diseases. In this review, we aim to highlight, with a translational intent, the molecular basis and the clinical indications of VPA.",
keywords = "Epigenetics, Epilepsy, Epileptogenesis, Neuroprotection, Pharmacology, Valproic acid",
author = "Michele Romoli and Petra Mazzocchetti and Renato D’alonzo and Sabrina Siliquini and Rinaldi, {Victoria Elisa} and Alberto Verrotti and Paolo Calabresi and Cinzia Costa",
year = "2019",
month = "1",
day = "1",
doi = "10.2174/1570159X17666181227165722",
language = "English",
volume = "17",
pages = "926--946",
journal = "Current Neuropharmacology",
issn = "1570-159X",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - Valproic acid and epilepsy

T2 - From molecular mechanisms to clinical evidences

AU - Romoli, Michele

AU - Mazzocchetti, Petra

AU - D’alonzo, Renato

AU - Siliquini, Sabrina

AU - Rinaldi, Victoria Elisa

AU - Verrotti, Alberto

AU - Calabresi, Paolo

AU - Costa, Cinzia

PY - 2019/1/1

Y1 - 2019/1/1

N2 - After more than a century from its discovery, valproic acid (VPA) still represents one of the most efficient antiepileptic drugs (AEDs). Pre and post-synaptic effects of VPA depend on a very broad spectrum of actions, including the regulation of ionic currents and the facilitation of GABAergic over glutamatergic transmission. As a result, VPA indirectly modulates neurotransmitter release and strengthens the threshold for seizure activity. However, even though participating to the anticonvulsant action, such mechanisms seem to have minor impact on epileptogenesis. Nonetheless, VPA has been reported to exert anti-epileptogenic effects. Epigenetic mechanisms, including histone deacetylases (HDACs), BDNF and GDNF modulation are pivotal to orientate neurons toward a neuroprotective status and promote dendritic spines organization. From such broad spectrum of actions comes constantly enlarging indications for VPA. It represents a drug of choice in child and adult with epilepsy, with either general or focal seizures, and is a consistent and safe IV option in generalized convulsive status epilepticus. Moreover, since VPA modulates DNA transcription through HDACs, recent evidences point to its use as an anti-nociceptive in migraine prophylaxis, and, even more interestingly, as a positive modulator of chemotherapy in cancer treatment. Furthermore, VPA-induced neuroprotection is under investigation for benefit in stroke and traumatic brain injury. Hence, VPA has still got its place in epilepsy, and yet deserves attention for its use far beyond neurological diseases. In this review, we aim to highlight, with a translational intent, the molecular basis and the clinical indications of VPA.

AB - After more than a century from its discovery, valproic acid (VPA) still represents one of the most efficient antiepileptic drugs (AEDs). Pre and post-synaptic effects of VPA depend on a very broad spectrum of actions, including the regulation of ionic currents and the facilitation of GABAergic over glutamatergic transmission. As a result, VPA indirectly modulates neurotransmitter release and strengthens the threshold for seizure activity. However, even though participating to the anticonvulsant action, such mechanisms seem to have minor impact on epileptogenesis. Nonetheless, VPA has been reported to exert anti-epileptogenic effects. Epigenetic mechanisms, including histone deacetylases (HDACs), BDNF and GDNF modulation are pivotal to orientate neurons toward a neuroprotective status and promote dendritic spines organization. From such broad spectrum of actions comes constantly enlarging indications for VPA. It represents a drug of choice in child and adult with epilepsy, with either general or focal seizures, and is a consistent and safe IV option in generalized convulsive status epilepticus. Moreover, since VPA modulates DNA transcription through HDACs, recent evidences point to its use as an anti-nociceptive in migraine prophylaxis, and, even more interestingly, as a positive modulator of chemotherapy in cancer treatment. Furthermore, VPA-induced neuroprotection is under investigation for benefit in stroke and traumatic brain injury. Hence, VPA has still got its place in epilepsy, and yet deserves attention for its use far beyond neurological diseases. In this review, we aim to highlight, with a translational intent, the molecular basis and the clinical indications of VPA.

KW - Epigenetics

KW - Epilepsy

KW - Epileptogenesis

KW - Neuroprotection

KW - Pharmacology

KW - Valproic acid

UR - http://www.scopus.com/inward/record.url?scp=85072939574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072939574&partnerID=8YFLogxK

U2 - 10.2174/1570159X17666181227165722

DO - 10.2174/1570159X17666181227165722

M3 - Review article

C2 - 30592252

AN - SCOPUS:85072939574

VL - 17

SP - 926

EP - 946

JO - Current Neuropharmacology

JF - Current Neuropharmacology

SN - 1570-159X

IS - 10

ER -